Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la base de données des Annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
Gabapentin and its salts and derivativesF1 I SEP / 98
Galantamine and its salts and derivativesF1 I OCT / 03
Gallamine triethiodideF1 I SEP / 98
Gallium and its saltsF1 I SEP / 98
Ganciclovir and its saltsF1 I SEP / 98
Ganirelix and its salts and derivativesF1 I MAY / 04
Gatifloxacin and its salts and derivativesF1 I JUL / 03
GefitinibF1 I SEP / 06
Gemcitabine and its saltsF1 I SEP / 98
Gemfibrozil and its saltsF1 I SEP / 98
Gemifloxacin and its saltsF1 I SEP / 06
Gentamicin and its salts and derivativesF1 I SEP / 98
Gentian Violet II DEC / 01
Glatiramer and its saltsF1 I SEP / 98
GlecaprevirPDL I SEP / 17
GliclazideF1 I SEP / 98
GlimepirideF1 I MAY / 04
GlipizideF1 I SEP / 98
Glucagon II SEP / 98
Glutamic acid and its salts gastric acidifiers U FEB / 99
GlutethimideF1 I SEP / 98
Glyburide and its salts and derivativesF1 I SEP / 98
Glyceroargentinate III SEP / 98
Glycopyrrolate or its salts

except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation

II DEC / 17
Glycopyrronium bromidePDL

including but not limited to glycopyrrolate, when used orally or for inhalation

I DEC / 17
Gold or its salts or derivativesPDL

including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection

I DEC / 13
GolimumabF1 I MAR / 11
Gonadorelin and its saltsF1 I SEP / 98
Gonadotropin, chorionicF1 human I SEP / 98
Gonadotropin, serumF1 human I SEP / 98
Goserelin and its saltsF1 I SEP / 98
Gramicidin and its salts for topical use U
Gramicidin and its salts and derivatives for ophthalmic use III JUN / 06
Granisetron and its saltsF1 I SEP / 98
GrazoprevirPDL I AUG / 16
Grepafloxacin and its salts and derivativesF1 I SEP / 99
Griseofulvin and its salts and derivativesF2 I SEP / 98
Guaifenesin U
Guanethidine and its saltsF1 I SEP / 98
GuselkumabPDL I MAR / 18

40 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled